Dopamine D2 receptor imaging inGilles de la Tourette syndrome

Objectives– to examine postsynaptic dopamine D2 receptors in Tourette syndrome (TS). Material and methods– Seventeen patients and a control group were investigated using single photon emission computed tomography (SPECT) and iodobenzamide (123I‐IBZM). Results– In neuroleptic treated patients (n=7) 123I‐IBZM‐binding was significantly reduced compared to both normal controls (P<0.0001) and unmedicated patients (P<0.001). In unmedicated patients (n=10) mean binding ratio did not differ from that of control group. Patients in advanced stages of the disease, however, revealed significantly reduced relative striatal binding compared to patients in the early stages (P<0.005) and normal controls (P<0.0001). Conclusion– The results lend further support to the hypothesis that the dopamine receptor is involved in TS pathology. During the natural course of the disease tics often improve in early adulthood. It is suggested that this spontaneous recovery from tics may be associated with reduced receptor binding capacity.

[1]  G. S. Golden,et al.  The relationship between stimulant medication and tics. , 1988, Pediatric annals.

[2]  C. Kirsch,et al.  SPECT imaging of dopamine D2 receptors with 123I‐IBZM: initial experience in controls and patients with Parkinson's syndrome and Wilson's disease , 1991, Nuclear medicine communications.

[3]  Mary M. Robertson,et al.  Annotation: Gilles de la Tourette syndrome--an update. , 1994, Journal of child psychology and psychiatry, and allied disciplines.

[4]  H. Singer,et al.  Abnormal dopamine uptake sites in postmortem striatum from patients with tourette's syndrome , 1991, Annals of neurology.

[5]  A. Alavi,et al.  In vivo SPECT imaging of CNS D-2 dopamine receptors: initial studies with iodine-123-IBZM in humans. , 1990, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[6]  C. Halldin,et al.  Comparison of the In Vitro Receptor Binding Properties of N‐[3H]Methylspiperone and [3H]Raclopride to Rat and Human Brain Membranes , 1990, Journal of neurochemistry.

[7]  R. Coppola,et al.  Tourette Syndrome: Prediction of Phenotypic Variation in Monozygotic Twins by Caudate Nucleus D2 Receptor Binding , 1996, Science.

[8]  M. Ichise,et al.  Dopamine D2 receptor SPECT imaging: basic in vivo characteristics and clinical applications of 123I-IBZM in humans. , 1993, Annals of Nuclear Medicine.

[9]  K. Leenders,et al.  Comparison of 123I‐IBZM SPECT and 11C‐raclopride PET findings in patients with parkinsonism , 1994, Nuclear medicine communications.

[10]  M. Trimble,et al.  Dopamine receptor availability in Tourette's syndrome , 1994, Psychiatry Research: Neuroimaging.

[11]  G. Sawle,et al.  PET studies of the presynaptic and postsynaptic dopaminergic system in Tourette's syndrome. , 1994, Journal of neurology, neurosurgery, and psychiatry.

[12]  L. Deecke,et al.  D2 Receptor Blockade by Flunarizine and Cinnarizine Explains Extrapyramidal Side Effects. A SPECT Study , 1995, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[13]  A. Shapiro,et al.  Controlled study of haloperidol, pimozide and placebo for the treatment of Gilles de la Tourette's syndrome. , 1989, Archives of general psychiatry.

[14]  A. Gjedde,et al.  D2-like dopamine receptor density in Tourette syndrome measured by PET. , 1997, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[15]  J. Coyle,et al.  Dopaminergic dysfunction in tourette syndrome , 1982 .

[16]  G. Erenberg,et al.  The natural history of Tourette syndrome: A follow‐up study , 1987, Annals of neurology.

[17]  R. Caprioli,et al.  Biogenic amine metabolism in tourette syndrome , 1979, Annals of neurology.

[18]  G. Stebbins,et al.  Adult tics in Gilles de la Tourette's syndrome , 1992, Neurology.

[19]  A. Alavi,et al.  In vitro and in vivo evaluation of [123I]IBZM: a potential CNS D-2 dopamine receptor imaging agent. , 1989, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[20]  L. Nee,et al.  Tourette syndrome: clinical and family studies. , 1982, Advances in neurology.

[21]  R. G. Manning,et al.  High affinity dopamine D2 receptor radioligands. 1. Regional rat brain distribution of iodinated benzamides. , 1991, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[22]  B. Shaywitz,et al.  Chronic, multiple tics of Gilles de la Tourette's disease. CSF acid monoamine metabolites after probenecid administration. , 1978, Archives of general psychiatry.

[23]  R. Bruun,et al.  The natural history of Tourette syndrome. , 1992, Advances in neurology.

[24]  L. Deecke,et al.  Dopamine D2 Receptor Imaging with SPECT: Studies in Different Neuropsychiatric Disorders , 1991, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[25]  J. Palacios,et al.  Dopamine receptors in human brain: Autoradiographic distribution of D2 sites , 1989, Neuroscience.

[26]  N. P. L. G. VERHOEFF,et al.  Dynamic SPECT in two healthy volunteers to determine the optimal time for in vivo D2 dopamine receptor imaging with123I‐IBZM using the rotating gamma camera , 1991, Nuclear medicine communications.